Aggressive Lymphomas

From the Journals

PDPK1 could be novel target in MCL

The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.

MD IQ

From the Journals

Time to rethink MCL treatment, trial design

Dr. Leonid Yavorkovsky of Kaiser Permanente San Jose Medical Center questions the traditional approach to treatment of class mantle cell lymphoma...

Pages